23.90Open23.90Pre Close0 Volume179 Open Interest300.00Strike Price0.00Turnover44.12%IV-12.74%PremiumDec 20, 2024Expiry Date55.11Intrinsic Value100Multiplier25DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.9718Delta0.0047Gamma4.44Leverage Ratio-0.0227Theta-0.0538Rho-4.31Eff Leverage0.0384Vega
Alnylam Pharmaceuticals Stock Discussion
Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024 | ALNY Stock News
ALNY BUY ALERT 🚨 DRUG NEWS MULTIPLE PRICE TARGET RAISES
No comment yet